MLTX insider transactions
MoonLake Immunotherapeutics (MLTX) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for MLTX
- Chief Financial Officer Bodenstedt Matthias sold $273,333 worth of Class A ordinary shares (13,653 units at $20.02) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,172,431 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Bodenstedt Matthias4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Santos Da Silva Jorge4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Bodenstedt Matthias4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Bvf Partners L P/Il4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Chief Scientific Officer Reich Kristian4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Santos Da Silva Jorge4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Chief Financial Officer Bodenstedt Matthias was granted 354,296 units of Class A ordinary shares, increasing direct ownership by 38% to 1,276,305 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Chief Financial Officer Bodenstedt Matthias converted options into 294,473 units of Class A ordinary shares and returned 294,473 units of Class C ordinary shares to the company, closing all direct ownership in the company (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Chief Scientific Officer Reich Kristian converted options into 35,389 units of Class A ordinary shares and returned 35,389 units of Class C ordinary shares to the company (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Chief Executive Officer Santos Da Silva Jorge converted options into 196,316 units of Class A ordinary shares and returned 196,316 units of Class C ordinary shares to the company, closing all direct ownership in the company (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Chief Executive Officer Santos Da Silva Jorge sold $2,974,700 worth of Class A ordinary shares (200,000 units at $14.87), decreasing direct ownership by 6% to 2,878,577 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Chief Scientific Officer Reich Kristian sold $3,012,462 worth of Class A ordinary shares (202,908 units at $14.85), closing all direct ownership in the company (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Chief Financial Officer Bodenstedt Matthias bought $98,808 worth of Class A ordinary shares (10,870 units at $9.09), increasing direct ownership by 2% to 627,536 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Former 10% Owner Chen Bihua sold $46,868,184 worth of Class A Ordinary Shares (6,499,978 units at $7.21) (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Chief Scientific Officer Reich Kristian converted options into 48,978 units of Class A ordinary shares and returned 48,978 units of Class C ordinary shares to the company, decreasing direct ownership by 77% to 35,389 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Director Moukheibir Catherine converted options into 23,500 units of Class A ordinary shares and sold $1,146,565 worth of Class A ordinary shares (23,500 units at $48.79) (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Director Bvf Partners L P/Il4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Director Sturge Simon4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Director Loy Spike4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Director Xavier Ramnik4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Director Moukheibir Catherine4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Director Phillips Andrew John4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Chief Executive Officer Santos Da Silva Jorge was granted 95,763 units of Class A ordinary shares, increasing direct ownership by 3% to 3,078,577 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Chief Scientific Officer Reich Kristian4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Chief Financial Officer Bodenstedt Matthias was granted 95,763 units of Class A ordinary shares, increasing direct ownership by 18% to 616,666 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Chief Scientific Officer Reich Kristian converted options into 111,949 units of Class A ordinary shares and returned 111,949 units of Class C ordinary shares to the company, increasing direct ownership by 101% to 84,367 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Director Bvf Partners L P/Il sold $100,003,200 worth of Class A Ordinary Shares (2,000,000 units at $50.00) (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Director Sturge Simon sold $9,186,120 worth of Class A ordinary shares (171,000 units at $53.72), decreasing direct ownership by 50% to 171,980 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Director Bvf Partners L P/Il4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Moukheibir Catherine4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Phillips Andrew John4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Xavier Ramnik4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Sturge Simon4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Loy Spike4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Santos Da Silva Jorge sold $6,803,044 worth of Class A ordinary shares (123,615 units at $55.03), decreasing direct ownership by 4% to 2,982,814 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Reich Kristian sold $6,540,710 worth of Class A ordinary shares (118,922 units at $55.00), decreasing direct ownership by 58% to 41,981 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Santos Da Silva Jorge sold $62,179 worth of Class A ordinary shares (1,125 units at $55.27), decreasing direct ownership by 0.04% to 3,106,429 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Reich Kristian sold $1,208,418 worth of Class A ordinary shares (21,078 units at $57.33), decreasing direct ownership by 10% to 99,502 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Santos Da Silva Jorge sold $3,555,400 worth of Class A ordinary shares (60,000 units at $59.26), decreasing direct ownership by 2% to 3,107,554 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Reich Kristian sold $3,654,800 worth of Class A ordinary shares (60,000 units at $60.91), decreasing direct ownership by 21% to 110,071 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Bodenstedt Matthias sold $5,917,368 worth of Class A ordinary shares (100,000 units at $59.17), decreasing direct ownership by 16% to 520,903 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Chen Bihua bought $3,524,297 worth of Class A Ordinary Shares (58,839 units at $59.90) (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Chen Bihua bought $16,800,343 worth of Class A Ordinary Shares (293,212 units at $57.30) (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Sturge Simon converted options into 342,980 units of Class A ordinary shares and returned 342,980 units of Class C ordinary shares to the company (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Bodenstedt Matthias converted options into 62,972 units of Class A ordinary shares and returned 62,972 units of Class C ordinary shares to the company, decreasing direct ownership by 47% to 294,473 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Santos Da Silva Jorge converted options into 3,167,554 units of Class A ordinary shares and returned 3,167,554 units of Class C ordinary shares to the company (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- Reich Kristian converted options into 2,569,458 units of Class A ordinary shares and returned 2,569,458 units of Class C ordinary shares to the company, increasing direct ownership by 100% to 196,316 units (SEC Form 4)4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Chen Bihua4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Chen Bihua4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Bvf Partners L P/Il4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Sturge Simon4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Xavier Ramnik4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Loy Spike4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Moukheibir Catherine4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Phillips Andrew John4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Bodenstedt Matthias4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Reich Kristian4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SEC Form 4 filed by Chen Bihua4 - MoonLake Immunotherapeutics (0001821586) (Issuer)